We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$92.4M
Cap. Flow
+$88.5M
Cap. Flow %
24.56%
Top 10 Hldgs %
19.65%
Holding
155
New
60
Increased
18
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$9.64M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$6.47M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$6.31M
4
CDNA icon
CareDx
CDNA
+$6.31M
5
VRCA icon
Verrica Pharmaceuticals
VRCA
+$6.28M

Top Sells

Rank Stock Value
1
IRD
Opus Genetics
IRD
+$15.5M
2
GNPX icon
Genprex
GNPX
+$6.81M
3
ANAB icon
AnaptysBio
ANAB
+$5.62M
4
COGT icon
Cogent Biosciences
COGT
+$4.86M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 82.98%
2 Financials 2.24%
3 Consumer Staples 0.95%
4 Industrials 0.89%
5 Technology 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENT
51
DELISTED
Intersect ENT, Inc
XENT
$2.96M 0.82%
141,856
+42,195
+42% +$974K
MORF
52
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.94M 0.82%
+46,541
New +$2.14M
EYPT icon
53
EyePoint Inc
EYPT
$1.2B
$2.94M 0.82%
+289,316
New +$3.26M
NUVA
54
DELISTED
NuVasive, Inc.
NUVA
$2.83M 0.79%
+43,133
New +$2.59M
IRON icon
55
Disc Medicine
IRON
$2.97B
$2.76M 0.77%
+6,800
New +$3.03M
PHAS
56
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.68M 0.74%
+775,000
New +$3.15M
DYN icon
57
Dyne Therapeutics
DYN
$4.9B
$2.59M 0.72%
+166,636
New +$3.22M
CFMS
58
DELISTED
Conformis, Inc. Common Stock
CFMS
$2.58M 0.72%
+104,355
New +$2.81M
MLTX icon
59
MoonLake Immunotherapeutics
MLTX
$1.55B
$2.55M 0.71%
250,000
– –
PROF
60
Profound Medical
PROF
$269M
$2.55M 0.71%
+126,427
New +$3.03M
TMPMU
61
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$2.54M 0.71%
254,000
– –
SNCE
62
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.54M 0.7%
12,500
– –
CHFW.U
63
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$2.44M 0.68%
250,000
– –
SRSAU
64
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$2.44M 0.68%
225,000
– –
CYTK icon
65
Cytokinetics
CYTK
$10.4B
$2.4M 0.67%
+103,262
New +$2.2M
IRD
66
Opus Genetics
IRD
$302M
$2.31M 0.64%
397,036
-1,671,494
-81% -$15.5M
WVE icon
67
Wave Life Sciences
WVE
$1.2B
$2.24M 0.62%
+398,997
New +$3.83M
LITS
68
Lite Strategy Inc
LITS
$30.9M
$2.19M 0.61%
+31,904
New +$2.23M
VREX icon
69
Varex Imaging
VREX
$523M
$2.17M 0.6%
+105,727
New +$2.26M
ADMS
70
DELISTED
Adamas Pharmaceuticals
ADMS
$2.16M 0.6%
+450,000
New +$2.35M
MCRB icon
71
Seres Therapeutics
MCRB
$48.4M
$2.15M 0.6%
+5,231
New +$2.41M
SYRE icon
72
Spyre Therapeutics
SYRE
$9.25B
$2.12M 0.59%
10,710
– –
PXS icon
73
Pyxis Tankers
PXS
$51.5M
$2.1M 0.58%
+508,948
New +$2.59M
CALA
74
DELISTED
Calithera Biosciences, Inc
CALA
$2.07M 0.57%
+42,695
New +$2.48M
HCAQ
75
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$2M 0.56%
+200,000
New +$2.05M
1 2
3
4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Altium Capital Management held 155 positions worth $360M, up 34% from $268M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Altium Capital Management deployed $88.5M of net new capital in Q1 2021, opening 60 new positions and adding to 18 existing holdings. Its largest new stake was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Opus Genetics, an estimated $15.5M trimmed.

  • Altium Capital Management's largest Q1 2021 buy was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.
  • Altium Capital Management added most to Verrica Pharmaceuticals in Q1 2021, an estimated $6.28M increase.
  • Altium Capital Management's biggest Q1 2021 reduction was Opus Genetics, cutting an estimated $15.5M.
  • Altium Capital Management fully exited AnaptysBio in Q1 2021, selling an estimated $5.62M.
  • Altium Capital Management's ten largest holdings make up 20% of its $360M portfolio in Q1 2021.
  • Altium Capital Management opened 60 new positions and closed 31 in Q1 2021.
  • Altium Capital Management's portfolio value rose 34% quarter-over-quarter to $360M.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.